

Ref No. NLL/CS/2017-311

Date: 14.02.2017

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Unaudited Financial Results.

Ref: Compliance under Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sirs,

Pursuant to captioned Regulations, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on December 31, 2016, as approved by the Board of Directors in their meeting held on even date i.e. February 14, 2017. A copy of the Limited Review Report is also enclosed herewith for your record please.

Kindly acknowledge receipt of the same and oblige.

Thanking you,

Yours faithfully,

For NECTAR LIFESCIENCES LIMITED


Sunder Lal
Company Secretary

Encl. as above



DATTA SINGLA & CO.
Chartered Accountants

SCO 2935-36, Level 1, Sector 22-C,
Chandigarh - 160 022 (INDIA)
Tele : +91-172-2707065, 5086551 / 52
Fax : +91-172-5019550

To Whomsoever It May Concern

We have reviewed the accompanying statement of unaudited financial results of **Nectar Lifesciences Limited** for the quarter and 9 Months ended **December 31, 2016** attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulation 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 and SEBI Circular dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the unaudited financial results and financial information for the Quarter and 9 Months ended December 31, 2015 which have been presented solely based on the financial information compiled by the Management.

For Datta Singla & Company
Chartered Accountants
Firm Regn. No. 066185N
* CHARTERED ACCOUNTANTS *
GAGANPREET SARG
PARTNER
CHANDIGARH
M. No.: 539158

Place: Chandigarh
Date: 14.02.2017

NECTAR LIFESCIENCES LIMITED


Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab,

Corporate Identification Number (CIN): L24232PB1995PLC016664

Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: sunderlal@neclife.com, Website : www.neclife.com

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2016 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended			Nine months ended	
		31-12-16	30-09-16	31-12-15	31-12-16	31-12-15
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1.	Income from Operations					
	(a) Gross Sales	46,969.43	44,160.31	43,380.52	128,752.06	128,689.47
	Less : Excise Duty	2,631.68	2,694.49	3,653.14	7,530.82	8,526.83
	Net Sales	44,337.75	41,465.82	39,727.38	121,221.24	120,162.64
	(b) Other Operating Income	0.00	0.00	1.10	26.10	2.78
	Total Income from Operations (net)	44,337.75	41,465.82	39,728.48	121,247.34	120,165.42
2.	Expenses					
	(a) Cost of Materials consumed	30,625.30	29,309.16	26,054.52	82,882.72	79,199.46
	(b) Purchase of Stock in Trade	404.28	290.78	429.28	926.25	2,322.46
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(170.19)	(641.52)	121.09	(293.27)	251.22
	(d) Employee benefits expense	1,816.84	2,089.28	2,205.72	5,888.29	6,112.95
	(e) Depreciation and amortisation expense	1,476.69	1,494.71	1,582.18	4,478.52	4,713.97
	(f) Other expenses	4,775.69	4,263.95	4,621.12	13,103.78	13,660.40
	Total Expenses	38,928.61	36,806.36	35,013.91	106,986.29	106,260.46
3.	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	5,409.14	4,659.46	4,714.57	14,261.05	13,904.96
4.	Other Income	222.33	127.46	171.89	495.43	425.62
5.	Profit from ordinary activities before finance costs and exceptional items (3+4)	5,631.47	4,786.92	4,886.46	14,756.48	14,330.58
6.	Finance costs	3,385.91	2,910.95	3,035.96	9,181.94	8,851.40
7.	Profit from ordinary activities after finance costs but before exceptional items (5-6)	2,245.56	1,875.97	1,850.50	5,574.54	5,479.18
8.	Exceptional Items	-	-	-	-	-
9.	Profit from ordinary activities before tax (7+8)	2,245.56	1,875.97	1,850.50	5,574.54	5,479.18
10.	Tax Expense	431.90	264.30	378.50	919.06	1,193.75
11.	Net Profit from ordinary activities after tax (9-10)	1,813.66	1,611.67	1,472.00	4,655.48	4,285.43
12.	Extraordinary Item (net of tax expense)	-	-	-	-	-
13.	Net Profit for the period (11-12)	1,813.66	1,611.67	1,472.00	4,655.48	4,285.43
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	Not applicable				
16.i	Earnings per Share (EPS) (before extraordinary items)					
	a) Basic	0.81	0.72	0.66	2.08	1.91
	b) Diluted	0.81	0.72	0.66	2.08	1.91
16.ii	Earnings per Share (EPS) (after extraordinary items)					
	a) Basic	0.81	0.72	0.66	2.08	1.91
	b) Diluted	0.81	0.72	0.66	2.08	1.91



Notes:

- The above financial results were reviewed by Audit Committee on February 13, 2017 and approved by the Board in its meeting held on February 14, 2017. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone unaudited financial results for the quarter and nine months ended on December 31, 2016.
- The company has adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under, from April 01, 2016 and accordingly, these standalone unaudited financial results (including figures for the quarter and nine months ended December 31, 2015) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
- The standalone financial results and other financial information for the quarter and nine months ended December 31, 2015 have not been audited or reviewed by the statutory auditors. However, the management has exercised necessary due diligence to ensure that the standalone unaudited financial results provide a true and fair view of the Company's affairs.
- Reconciliation of Net profit (Standalone) for the quarter and nine months ended December 31, 2015 under Indian GAAP (Previous GAAP) and Ind AS is as under:

Particulars	Quarter ended 31.12.2015	Nine Months ended 31.12.2015
	Unaudited	Unaudited
Net Profit for the quarter as per previous GAAP		
Add/ (Less) : Adjustment for GAAP Differences		
Impact of Depreciation/ Amortization	620.50	1,861.48
Impact of Intangible Assets	(955.88)	(3,048.56)
Deferred tax on above adjustments	67.30	258.65
Net Profit for the quarter as per Ind AS	1,472.00	4,285.43

- The company is exclusively in the pharmaceutical business segment.

Dated: 14.02.2017
Place: Chandigarh



By Order of the Board of Directors
of Nectar Lifesciences Limited

(Divesh Dua)
Chief Executive Officer & Director